Checkpoint Therapeutics Inc (NASDAQ:CKPT)
| 1.57 Delayed Data As of Sep 22 |  -0.13 / -7.65%Today’s Change | 1.54 Today|||52-Week Range 11.50 | -69.28% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $34.8M |
Company Description
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
Contact Information
Checkpoint Therapeutics, Inc. 95 Sawyer Road Waltham Massachusetts 02453 |
Employees
Shareholders
| Other institutional | 9.53% |
| Mutual fund holders | 3.45% |
| Individual stakeholders | 11.83% |
Top Executives
| James F. Oliviero | President, Chief Executive Officer & Director |
| William Garrett Gray | Chief Financial Officer, Secretary & Treasurer |
| Jaclyn Jaffe | Head-Investor Relations |
